Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18929661 | 0.85 | FAAH (0.36) | FAAHCAPN1TSHRHPGDGAA | |
| SCHEMBL23133369 | 0.80 | FAAH (0.46) | FAAHCAPN1TSHRHPGDGAA | |
| SCHEMBL20643520 | 0.80 | FAAH (0.55) | FAAHCAPN1TSHRHPGDGAA | |
| SCHEMBL23602769 | 0.78 | CD40 (0.43) | FAAHTSHR | |
| SCHEMBL21350264 | 0.77 | EPHX2 (0.34) | FAAHCAPN1TSHRHPGD | |
| SCHEMBL23692609 | 0.77 | POLB (0.40) | HPGDGAA | |
| SCHEMBL25868103 | 0.77 | — | — | |
| SCHEMBL25868117 | 0.77 | — | — | |
| SCHEMBL29323653 | 0.77 | FAAH (0.40) | FAAHCAPN1TSHRHPGD | |
| SCHEMBL26706577 | 0.76 | FAAH (0.61) | FAAHCAPN1TSHRGAARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | FAAH 3378/4885CAPN1 2772/4885TSHR 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.